List of Excipients in Branded Drug ADVIL ALLERGY SINUS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL ALLERGY SINUS	chlorpheniramine maleate, ibuprofen, pseudoephedrine hcl	0573-0188	CARNAUBA WAX	2027-02-28
Haleon US Holdings LLC	ADVIL ALLERGY SINUS	chlorpheniramine maleate, ibuprofen, pseudoephedrine hcl	0573-0188	CELLULOSE, MICROCRYSTALLINE	2027-02-28
Haleon US Holdings LLC	ADVIL ALLERGY SINUS	chlorpheniramine maleate, ibuprofen, pseudoephedrine hcl	0573-0188	CROSCARMELLOSE SODIUM	2027-02-28
Haleon US Holdings LLC	ADVIL ALLERGY SINUS	chlorpheniramine maleate, ibuprofen, pseudoephedrine hcl	0573-0188	FD&C RED NO. 40	2027-02-28

Last updated: October 4, 2026

Advil Allergy Sinus is an immediate-release OTC combination of ibuprofen 200 mg and pseudoephedrine hydrochloride 30 mg per caplet. Its commercial opportunity is driven less by novel active-ingredient exclusivity than by formulation quality, compliant labeling, supply reliability, private-label substitution, and differentiated delivery formats. The strongest excipient opportunities are taste and swallowability improvements, moisture and stability control, lower-cost direct compression, and line extensions that preserve the ibuprofen-pseudoephedrine therapeutic proposition.

Advil Allergy Sinus Excipient Strategy and Commercial Opportunities

What is the composition of Advil Allergy Sinus?

The U.S. product combines an analgesic and anti-inflammatory, ibuprofen, with a systemic nasal decongestant, pseudoephedrine hydrochloride.

Attribute	Advil Allergy Sinus
Dosage form	Oral coated caplet
Ibuprofen strength	200 mg
Pseudoephedrine hydrochloride strength	30 mg
Drug category	OTC internal analgesic and nasal decongestant
Primary uses	Sinus pressure, congestion, headache, minor aches and pains associated with allergy or cold symptoms
Regulatory route	OTC monograph-based marketing in the United States
Biosimilar relevance	None
Primary commercial risks	Generic and private-label substitution, pseudoephedrine controls, supply cost, consumer adherence

The listed inactive ingredients for the U.S. caplet include excipients used for binding, disintegration, lubrication, coating, color, flow control, and tablet stability. The label identifies materials such as microcrystalline cellulose, croscarmellose sodium, pregelatinized starch, povidone, colloidal silicon dioxide, sodium lauryl sulfate, stearic acid, hypromellose, polyethylene glycol, titanium dioxide, and FD&C Blue No. 1.[1]

The exact excipient system can vary by market, manufacturing site, dosage form, and product revision. Regulatory assessment should use the current market-specific label and manufacturing dossier.

What excipient functions are most important in the formulation?

The formulation must accommodate two active ingredients with different physical and regulatory characteristics.

Ibuprofen loading and compaction

Ibuprofen has a relatively high dose compared with many OTC active ingredients. It can present poor flow, elastic deformation, sticking, and variable compression behavior. Microcrystalline cellulose and pregelatinized starch can support tablet strength and content uniformity. Povidone can improve granule cohesion where wet or dry granulation is used.

A direct-compression formulation may reduce processing steps and manufacturing cost, but it requires tight control of:

• Particle-size distribution
• Bulk density
• Flowability
• Lubricant concentration
• Compression force
• Blend uniformity

Over-lubrication with stearic acid or another hydrophobic lubricant can slow disintegration and dissolution. A formulation optimized for lowest manufacturing cost may therefore create performance risk if the active ingredients or excipient grades change.

Pseudoephedrine hydrochloride handling

Pseudoephedrine hydrochloride is water soluble and can affect blend segregation, moisture behavior, and dissolution. Its lower dose relative to ibuprofen increases the importance of blend uniformity. A formulation with large ibuprofen particles and fine pseudoephedrine particles may segregate during transfer or tableting.

Particle engineering, controlled addition order, and low-shear blending can be more commercially valuable than adding a complex excipient. The objective is to maintain uniformity without increasing tablet weight or production time.

Disintegration and dissolution

Croscarmellose sodium and pregelatinized starch can support rapid tablet breakup. The target is rapid release of both actives without compromising mechanical strength or coating integrity.

A development program should compare:

1. Superdisintegrant level and grade
2. Intra-granular versus extra-granular addition
3. Tablet porosity
4. Lubrication time
5. Coating weight gain
6. Dissolution after accelerated storage

The commercial advantage is a robust product that maintains release performance after exposure to heat and humidity.

Film coating and swallowability

A film coating can reduce chalkiness, improve appearance, mask taste, and protect the tablet from abrasion. Hypromellose and polyethylene glycol are common coating components. Colorants help distinguish the product and support brand recognition.

The coating should remain thin enough to avoid unnecessary tablet weight and dissolution delay. An optimized coating system can create commercial value through:

• Better swallowability
• Lower tablet friability
• Reduced dusting
• Improved color consistency
• Easier visual identification
• Better resistance to transport damage

What formulation improvements could create commercial opportunities?

The most realistic opportunities are incremental rather than dependent on new active ingredients.

Smaller or easier-to-swallow caplets

Ibuprofen 200 mg accounts for most of the active mass. Reducing caplet size requires higher-density excipients, improved compaction, or a different manufacturing process. A smaller caplet can improve adherence for consumers who use the product during acute sinus symptoms.

Potential approaches include:

• High-density microcrystalline cellulose
• Co-processed cellulose-based excipients
• Roller compaction
• Optimized particle-size distribution
• Lower coating weight
• Bilayer or multilayer compression only if segregation can be controlled

The business case depends on whether the size reduction is visible to consumers and whether it can be achieved without higher unit cost.

Faster perceived relief

A rapid-disintegration or rapid-dissolution platform may support a differentiated product claim where allowed by the applicable OTC labeling framework. Excipient changes could include a more efficient superdisintegrant system, porous granules, or a rapidly wetting coating.

The formulation cannot imply faster clinical relief solely from faster tablet disintegration. Any comparative claim would require appropriate performance and clinical support.

Lower-moisture formulation

Moisture control can improve stability, packaging flexibility, and supply-chain resilience. Relevant approaches include:

• Low-moisture excipient grades
• Moisture-barrier film coating
• High-barrier blister packaging
• Desiccant-equipped bottles
• Reduced water activity during processing
• Moisture-resistant bottle closures

A lower-moisture process can reduce degradation and tablet softening, but packaging savings must be weighed against material cost and consumer convenience.

Taste and mouthfeel control

Although the caplet is swallowed whole, taste can become relevant if the coating chips or if consumers split, chew, or hold the tablet in the mouth. A more robust film coat and lower surface dust can reduce aversive sensory experiences.

Taste-masking technology is more commercially relevant for chewable, orally disintegrating, liquid, or powder formats than for the conventional caplet.

Lower-cost formulation

A private-label or contract-manufacturing product can compete by reducing excipient count and simplifying processing. A cost-down program should prioritize:

• Fewer excipient grades
• Direct compression where feasible
• Standardized coating materials
• Lower coating weight
• Reduced blend and transfer losses
• Common tooling across product sizes
• Dual sourcing of critical excipients

Cost reduction must preserve dissolution, dosage uniformity, appearance, and stability. The lowest-cost formulation is not commercially attractive if it causes batch failures or increases regulatory change-control requirements.

What excipient systems are suitable for private-label or store-brand products?

Private-label manufacturers can use the same active-ingredient combination while differentiating through packaging, dosage form, price, and channel placement. The core excipient platform should be selected for broad manufacturing compatibility.

Commercial objective	Excipient or process direction	Main benefit	Main risk
Lowest unit cost	Direct compression with standard cellulose and starch grades	Fewer process steps	Segregation and flow problems
High robustness	Granulation with povidone and starch	Better compactability	Higher processing cost
Faster disintegration	Croscarmellose sodium optimization	Rapid tablet breakup	Reduced tablet strength
Better appearance	Hypromellose-based film coat	Brand differentiation	Coating cost and dissolution impact
Moisture protection	Barrier coating and high-barrier packaging	Longer stability margin	Higher packaging cost
Smaller caplet	High-density excipients and compression optimization	Improved swallowability	Higher tooling and development cost
Premium positioning	Colored, polished, low-dust coated caplet	Consumer recognition	More complex change control

Private-label entry is most feasible when the product uses conventional inactive ingredients already accepted in oral immediate-release tablets. A novel excipient or unfamiliar delivery platform would increase regulatory and supply risk without necessarily improving the consumer proposition.

What FDA regulatory issues apply to Advil Allergy Sinus?

The U.S. product is regulated as an OTC drug. Ibuprofen is covered by the FDA OTC monograph framework for internal analgesic, antipyretic, and antirheumatic products. Pseudoephedrine is covered under the OTC nasal decongestant framework, subject to applicable conditions, labeling, and legal controls.[2][3]

The formulation must comply with:

• Active-ingredient conditions in the applicable monographs
• Permitted dosage and directions
• Required warnings
• Child-safety packaging requirements
• Good manufacturing practice requirements
• Inactive-ingredient controls
• Product-specific labeling and reporting obligations

Pseudoephedrine also carries supply-chain and retail controls under federal law. The Combat Methamphetamine Epidemic Act imposes retail sales limits, purchase-record requirements, identification controls, and storage obligations for scheduled listed chemical products.[4]

Excipient changes can trigger regulatory obligations even when the active ingredients remain unchanged. Material changes should be assessed for effects on dissolution, stability, dosage uniformity, appearance, labeling, and manufacturing controls.

What patent and exclusivity protections cover Advil Allergy Sinus?

The active ingredients are established OTC substances, and the product does not depend on biologic exclusivity or a new chemical entity period. There is no biosimilar pathway for this product.

The principal competitive barriers are therefore operational and regulatory:

• Brand recognition
• Retail distribution
• Consumer loyalty
• Formulation know-how
• Manufacturing scale
• Packaging and supply-chain compliance
• Pseudoephedrine purchasing controls
• Trademark rights
• Potentially applicable formulation or process patents

A product-specific patent conclusion requires a current search of U.S. Patent and Trademark Office records, FDA listings, and litigation databases. The public label alone does not establish whether any formulation or process patent remains enforceable.

Are there Orange Book patents for Advil Allergy Sinus?

The Orange Book primarily covers approved prescription drug products and does not function as the principal patent listing system for conventional OTC monograph products. Advil Allergy Sinus should not be analyzed as an Orange Book exclusivity asset in the same manner as a prescription new chemical entity.

This limits the relevance of:

• Paragraph IV certification
• Hatch-Waxman litigation
• New chemical entity exclusivity
• Prescription drug patent-term restoration

A competing OTC product can generally enter by satisfying the applicable monograph conditions and other FDA requirements. Brand, trademark, manufacturing, and distribution rights remain separate issues.

When does Advil Allergy Sinus lose exclusivity?

The product does not have a conventional prescription-drug exclusivity cliff. The active ingredients have long histories of OTC use, and generic or store-brand competition can arise under the applicable OTC regulatory framework.

The commercial exclusivity profile is better described as follows:

Protection type	Relevance
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orange Book patent listing	Generally not the primary framework
OTC monograph protection	Applies through compliance with FDA conditions
Trademark protection	Protects brand identifiers, not the active-ingredient combination
Formulation patents	May apply if valid and enforceable
Manufacturing know-how	Can create practical but nonexclusive barriers
Retail and distribution scale	Important commercial barrier
Pseudoephedrine controls	Increase operational complexity for competitors

The absence of a conventional exclusivity period does not eliminate commercial value. It shifts value toward brand equity, shelf placement, quality consistency, and differentiated packaging or dosage form.

What generic launch risks exist for Advil Allergy Sinus?

Generic and private-label launch risk is high for the conventional caplet because the actives are established, the dosage form is familiar, and consumers can compare products on price.

High-risk substitution factors

• Same ibuprofen and pseudoephedrine strengths
• Similar immediate-release caplet
• Common excipient architecture
• Strong retailer incentive to promote store brands
• Limited clinical differentiation between compliant products
• OTC consumer price sensitivity

Factors that can protect premium pricing

• Smaller or easier-to-swallow caplet
• Faster disintegration supported by evidence
• Superior moisture stability
• Better packaging convenience
• Stronger brand recognition
• Clearer symptom-positioning within permitted labeling
• Multi-pack and travel formats
• Reliable year-round availability

A generic product does not need to replicate every inactive ingredient. It generally needs to meet applicable quality, performance, labeling, and manufacturing requirements.

Which companies compete with Advil Allergy Sinus?

Competition comes from branded OTC manufacturers, retailers, and private-label suppliers. Relevant competitive sets include:

• Combination ibuprofen-pseudoephedrine products
• Ibuprofen products paired with non-systemic decongestants
• Acetaminophen-pseudoephedrine combinations
• Pseudoephedrine products without an analgesic
• Phenylephrine-based oral decongestants
• Single-ingredient ibuprofen plus separate allergy medicines
• Nasal sprays and other non-oral congestion products

The most direct substitutes are products with the same active ingredients and strengths. Indirect substitutes compete for the same consumer need but may have different safety profiles, dosing schedules, and regulatory positioning.

A formulation developer should benchmark:

1. Tablet dimensions
2. Coating type
3. Disintegration time
4. Dissolution profile
5. Packaging format
6. Unit price
7. Retail availability
8. Consumer reviews concerning swallowing and stomach tolerance

What licensing and manufacturing opportunities exist?

Excipient suppliers can pursue licensing or supply agreements in four areas.

Co-processed excipient platforms

A co-processed filler-binder-disintegrant system can simplify formulation development and reduce batch-to-batch variability. The strongest commercial target is a system that supports direct compression while maintaining rapid dissolution.

Film-coating technology

A coating supplier can offer improved moisture protection, lower weight gain, or reduced defect rates. The value proposition must be demonstrated against standard hypromellose systems.

Continuous manufacturing

Continuous blending or compression could reduce residence time, improve process control, and lower labor costs. The main barriers are equipment investment, validation, and control-strategy complexity.

Packaging and stability systems

High-barrier blister materials, induction-sealed bottles, and desiccant closures can extend stability or reduce complaints. Packaging innovation may produce a clearer return than a novel excipient because it can address moisture, tamper evidence, and portability simultaneously.

Licensing value is highest when the technology provides a measurable benefit that is difficult to reproduce with standard excipients.

How should an R&D team prioritize excipient development?

A practical development sequence is:

1. Confirm the target market, label, strengths, and dosage form.
2. Characterize ibuprofen and pseudoephedrine particle properties.
3. Screen standard direct-compression and granulation platforms.
4. Establish dissolution and disintegration targets.
5. Evaluate lubricant sensitivity and blend segregation.
6. Test moisture and temperature stress.
7. Compare coating systems for appearance, friability, and release.
8. Select packaging with the lowest total cost of ownership.
9. Complete regulatory assessment for all excipient and process changes.
10. Protect trade secrets and assess patentability for novel processes or compositions.

The best near-term opportunity is usually a robust, low-cost, rapidly disintegrating coated caplet rather than a complex modified-release system. Modified release would introduce clinical, regulatory, and consumer-use complexity without a clear need for this acute-symptom product.

Key Takeaways

• Advil Allergy Sinus contains ibuprofen 200 mg and pseudoephedrine hydrochloride 30 mg per U.S. caplet.
• The commercial opportunity is formulation-led because the active ingredients are established OTC substances.
• The most valuable excipient goals are rapid disintegration, strong tablet integrity, moisture resistance, and low manufacturing cost.
• Microcrystalline cellulose, pregelatinized starch, povidone, croscarmellose sodium, lubricants, and film-coating polymers form a conventional platform for development.
• Private-label and generic substitution risk is high because the product has no conventional prescription exclusivity cliff.
• Pseudoephedrine controls create operational barriers but do not provide durable product exclusivity.
• Orange Book and Paragraph IV analysis is less relevant than OTC monograph compliance, trademarks, formulation patents, manufacturing know-how, and retail execution.
• Packaging, coating, and co-processed excipient technologies offer the clearest licensing opportunities.
• A smaller, easier-to-swallow, rapidly disintegrating caplet is the most commercially credible line-extension strategy.

FAQs

Can a generic use different excipients from Advil Allergy Sinus?

Yes. A competing product generally does not need to duplicate the branded product’s inactive ingredients. It must meet applicable FDA quality, performance, labeling, and manufacturing requirements.

Is pseudoephedrine an excipient in Advil Allergy Sinus?

No. Pseudoephedrine hydrochloride is an active ingredient and nasal decongestant. Excipients are inactive formulation components used to manufacture and protect the dosage form.

Would an orally disintegrating Advil Allergy Sinus tablet be commercially attractive?

It could improve convenience, but the format would create taste-masking, dose-loading, stability, packaging, and regulatory challenges. A conventional coated caplet is more straightforward for this active combination.

Can a novel excipient create patent protection for the product?

Potentially, if the excipient system produces a novel and non-obvious composition or manufacturing process. Patentability would depend on claim scope, prior art, enablement, and commercial use, not merely on substituting one standard excipient for another.

Does Advil Allergy Sinus have biosimilar competition?

No. Biosimilar rules apply to biologic products. Advil Allergy Sinus is a conventional small-molecule OTC combination product and faces generic, private-label, and branded OTC competition instead.

References

1. DailyMed. (n.d.). Advil Allergy Sinus: Ibuprofen and pseudoephedrine hydrochloride tablet, film coated. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
3. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use.
4. U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act requirements for retail sellers of scheduled listed chemical products.